Partnering Platform for Solution Providers

Solution providers are encouraged to partner with other companies in order to provide an optimal solution for the Lot(s) of interest. This platform provides potential Solution Providers with an opportunity to present their partnering requirements and identify suitable partners.

Please complete the form using the link below in order to provide us with your partnering needs. Short presentations or recordings can also be submitted.

Submit your partner request

 

Download the table here

Company NamePROVIDING solution for Lot No.SEEKING solution for Lot No.Short description of your proposed solutionShort description of your partnering needsContact Person/EmailPresentation and/or recording
AIT Austrian Institute of Technology GmbHLot 1(Targeted) DNA methylation sequencing, short NAs, exosomes, preanalytics, Library prepTarget enrichment companies, sequencing solution providersChrista Noehammer
christa.noehammer@ait.ac.at
AIT slides
Bahia SoftwareLot 4Lots 1,2,3Bahia Software has significant experience developing software platforms for hospitals and research organizations. Bahia Software proprietary platform for Tumour Boards is currently in several Spanish hospitals and the company is working on R&D projects to facilitate reporting solutions from Liquid Biopsy analysis. Bahia Software may also contribute with its knowledge and successful experience in previous European PCP projects. No specific partnering needs. Very open to collaborate with organizations more interested in Lots 1, 2 and 3Sergio Gomez
sergio.figueiras@bahiasoftware.es
Bahia slides
BC PlatformsLot 4Modular Genomic Data management and -Analysis solution for automation of Genomic data production from Raw data to actionable report. Integration of various secondary analysis pipelines, QC and variant interpretation/reporting tools from partners.Partners for secondary analysis, QC, variant interpretation and actionable reporting are welcomed. BC Platforms provide the ovarall workflow from raw data to these integrated reports in a CE-IVDR solution established on the market. Open for customization and integration to our modular offering.Henrik Plym-Forshell
henrik.plym-forshell@bcplatforms.com
DNVLot 4Risk mitigation and quality assuranceLooking to partner with providers of analysis software, reagents, sequencers etc. to ensure pipelines, computing infrastructure etc. is implemented safely and responsibly.Courtney Nadeau
courtney.david.nadeau@dnv.com
DNV slides
EuformaticsLot 3Clinical NGS variant interpretation and quality control softwareSecondary analysis, kit providers, sequencer manufacturersTommi Kaasalainen
tommi.kaasalainen@euformatics.com
Euformatics slides
fragmentiX Storage Solutions GmbHLot 3Trusted data environment by using SECRET SHARING with fragmentiX CLUSTER appliancesLooking for partners, resellers, customersWerner Strasser
ws@fragmentix.com
fragmentiX slides
Geneyx Genomex LtdLot 3An AI-driven platform enables accurate analysis and interpretation of Whole Genome Sequencing (WGS) data. Produces rapid diagnosis at the highest diagnostics yields: >65%. Automated Phenotype – Genotype association – connecting disease symptoms to causal genes. The impact: Faster and better clinical diagnosis and distilling novel findings for targeted and personalized therapeutics.We may want to partner with more clinical genetic databasesRaviv ITZHAKY
raviv@geneyx.com
Geneyx slides
Genuity ScienceLot 1,2,3,4Lot 1,2,3,4Genuity Science is a CAP accredited genomics facility and has  proven competencies in a range of capabilities including sample handling and processing (blood, saliva, tissue and tissue blocks) for genomic WGS analysis. Our organisation has automated and semi-automated bioinformatic pipelines for generation of a variety of reports. We have an end to end integrated genomic lab service delivery platform.We are seeking partners potentially in the area of pre-analytics and library prep and also in the area of integrated reporting. We have the ability and desire to partner across all lots. We have a strong sample handling, NGS and bioinformatic delivery platform already established but would be keen to partner up to bring innovation not only to the project but also into our facility through collaboration. The area of least development for us is around the clinical decision support.David Kavanagh
david.kavanagh@genuitysci.com
Please enquire for slides
HTG Molecular DiagnosticsLot 1,2,4Extraction-free Transcriptome and RNA-Panel Library Prep and Data Analysis SolutionWe are interested in partnering with Lot 2 and Lot 4 providers and also with QC control providers in Lot1. Looking forward to a great partnership!Selina Gaertner
sgaertner@htgmolecular.com
HTG slides
iCellate MedicalLot 4End-to–end cancer NGS solution with strict adherence to clinical guidelines in ISO15189 accredited laboratory based on innovative sample types and analysesUniversity clinic with cancer patient management ready to merge Multidisciplinary Cancer Conference (MCC) with Molecular Tumor Board (MTB) to provide integrated management decision supportChrister Ericsson
christer.ericsson@icellate.se
iCellate slides
Integrated DNA TechnologiesLot 1Lot 1We offer highly innovative solutions for NGS library preparation (DNA/RNA) of challenging clinical samples, targeted enrichment (hybridization capture and amplicon sequencing) and normalization. We are also partnering with suppliers for extraction of nucleic acids and automation.We are looking for providers of products in areas: pre-analytics (collection, storage and transport of specimen), QC of nucleic acids (assessment of amount, purity, integrity, fragment size distribution of NA and tumor content), QC of library prepped DNA (quantification and size distribution) and reference materials.K. Julia Duda
kduda@idtdna.com
IDT slides
LGC SeracareLot 1Multiplexed biosynthetic reference materials in gDNA/RNA, FFPE and ctDNA format, including custom solutions and imuno-oncologyWe would like to partner with a provider of nucleic acid extraction, library prep and target enrichment solutions requiring reference materials for analytical validation and CE-IVD readiness of the platform.Krystyna Nahlik
krystyna.nahlik@lgcgroup.com
LGC slides
Maxeler TechnologiesLot 3,4Fast and efficient processing of sequencing data, explainable AI for drug selection, integrated in secure data analysis and collaboration platform.Partners in Lot 3 & 4 that are in need for accelerated sequence alignment algorithms, improved AI-based decision making for drug selection, or a platform for secure data sharing, analysis and dashboarding.Tobias Becker
tbecker@maxeler.com
Maxeler slides
MicronomaLot 4Microbiome Aware Liquid BiopsyWe would like to partner with company specialized in reporting results to patients and clinicians.Sandrine Miller-Montgomery
sandrine.miller@micronoma.com
Micronoma slides
Molecular HealthLot 4MH Guide is a NGS platform independent interpretation solution of NGS data.Thomas Holtrup
thomas.holtrup@molecularhealth.com
Molecular HealthLot 4MH Guide quickly and accurately identifies and interprets genetic variants in tumors. The MH Guide report helps treatment providers choose therapy options and clinical trials that match the cancer patients molecular profile. MH Guide is an IVD medical device approved in the EU.Katrin Stecker
katrin.stecker@molecularhealth.com
Molecular Health slides
New England BiolabsLot 1Lot 1Integrated library prep and target enrichment for high-sensitivity variant callingNucleic acid extraction and analytical QC providers, plus downstream bioinformatics/variant calling.Andrew Barry
barrya@neb.com
NEB slides
Nostos Genomics GmbHLot 3 and 4Lot 3Analyzing data to find disease-causing mutations in DNA is a crucial step in genetic testing. Our AI-based platform AION automates the process of variant interpretation to reduce cost, time, and other constraints associated with this process while improving quality. To do this, we use machine learning algorithms that can analyze variants with high accuracy while providing insights into the reasoning process.Interested in partnering with providers that focus on secondary analysis / bioinformatics.Ansgar Lange
ansgar.lange@nostos-genomics.com
Oncompass MedicineLot 4Multiparameter-based digital drug-assignment for treatment planning in precision oncology.Partnering preferred with an ESCAT- or other single biomarker-based reporting solution, which represents the standard-of-care in reporting. This could be complemented with the innovative multiparametric digital solution of Oncompass Medicine.Barbara Vodicska on behalf of Istvan Petak
barbara.vodicska@oncompassmedicine.com
Oncompass slides
Phenosystems SALot 3Lot 3We have developed GensearchNGS, a GUI based integrated NGS data analysis software from FastQ alignment to technical reports about variants and patient centric database. This software is commercialized and used in European diagnostics laboratories. The software runs on Desktops as well as server installations.Data storage, integrating clinical data, connection to EHR systemsDavid Atlan
phenosystems@gmail.com
Phenosystems slides
RocheLot 4Robert Bulte
ROBERT.BULTE@ROCHE.COM
Roche slides
Roche DiagnosticsLot 4Navify Mutation Profiler – a clinical decision support toolseamless integration of decision support tools & molecular tumor boards in a routine diagnostic processGerrit Schramm
gerrit.schramm@roche.com
Roche slides (2)
SaphetorLot 3Lot 1,2,4Saphetor’s suite of services offers clinicians intuitive, data-driven solutions to make faster, more accurate diagnoses, and informed decisions for the selection of the best therapies, especially for cancer and difficult to diagnose conditions, such as rare diseases or cognitive impairment.Aljosa Zavisic
aljosa.zavisic@varsome.com
Semmelweis UniversityLot 4Miklos Garami
miklos.garami@gmail.com
SeqOneLot 3Lot 2SeqOne, a bioinformatics company based in Montpellier, develops cutting edge genomic analysis tools for NGS data interpretation for the diagnosis of constitutional, hereditary diseases and somatic diseases in the context of personalised medicine.
The platform offers the following key features:
– State-of-the-art bioinformatics capable of identifying all relevant variants, including challenging variants traditional bioinformatic tools struggle to isolate,
– An end-to-end solution that covers the full analysis from FastQ file to final clinical report minimising human intervention to reduce turnaround time and manual inputs,
– A catalog of bioinformatic applications each designed for a specific medical need and capable of addressing both somatic and constitutional requirements
– Built-in quality control and certification support tools that ensure the quality and accuracy of your results while simplifying the lab certification process, and
– An easy-to-use interpretation interface that simplifies the task of biologists interpreting the data while giving them all the information they need to validate interpretations with confidence.
As IT company and based on our expertises & strategic road map, we can cover the lot 3 and 4 of this “INtegrated and STANDardized NGS workflows FOR Personalized therapy” project:
• Development of common guidelines on implementing NGS in oncology practice at the data interpretation level (detection of variant, classification, interpretation and reporting)
• Development of common protocols for data-sharing
• Development of tools for interactive-Consults (molecular tumor boards)
• Real time information of approved drug & clinical trial
• Develop patient- matching tool …


Further we are looking to find partner that can answer the requirements of lot 2
Jean Marc Holder
jm.holder@seqone.com
SeqOne slides
University Medical Center GroningenLot 4not a solution provider, but end userAcademic partner for validation of tools for variant interpretation and reporting, and interaction between MTBsLeon van Kempen
l.van.kempen@umcg.nl
UMCG slides